Oral etoposide in the treatment of hormone-refractory prostate cancer.
Cancer
; 74(1): 100-3, 1994 Jul 01.
Article
in En
| MEDLINE
| ID: mdl-8004566
ABSTRACT
BACKGROUND:
Hormone-refractory prostate cancer generally remains a chemotherapy-resistant tumor and therefore warrants the continued evaluation of promising agents.METHODS:
Twenty-two eligible patients with hormone-refractory prostate cancer were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28-day cycle. Response was evaluated using standard solid tumor response criteria.RESULTS:
There were two partial responses of 6 and 14 months' duration, respectively. Two patients had disease stabilization, one for 6 months and one for 12 months. Median survival was 31 weeks, with an overall 1-year survival of 30%. Reversible alopecia and myelosuppression were the primary toxicities noted.CONCLUSIONS:
Single-agent oral etoposide has minimal activity in patients with hormone-refractory prostate cancer.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Adenocarcinoma
/
Etoposide
Limits:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cancer
Year:
1994
Document type:
Article